RxDoctor Payments DataLook up a doctor →

Nelson Ploch, MD

Urology · North Charleston, SCNPI 1205824489

Payments from drug & device makers

$9,794in general payments, 2019–2025

Across 505 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Pfizer$1K
  • Sumitomo Pharma America, Inc.$861
  • Endo Pharmaceuticals Inc.$608
  • AbbVie$419
  • Coloplast$401
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,57698%
  • Education$2182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,794 in reported general payments places this provider in the 75th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,258,357
Medicare patients
1,741
Services billed
21,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide121$1,694,248
GemtesaVibegron333$322,302
MyrbetriqMirabegron168$147,807
Testosterone Cypionate958$35,649
Alfuzosin Hcl ErAlfuzosin Hcl1,424$33,216
Testosterone123$26,775
Dutasteride890$25,783
Mirabegron ErMirabegron26$20,584
Tolterodine Tartrate ErTolterodine Tartrate181$14,681
NitrofurantoinNitrofurantoin Macrocrystal551$14,354
Tamsulosin Hcl870$11,949
Estradiol73$8,848
Ciprofloxacin Hcl592$8,017
Solifenacin Succinate253$7,331
Fesoterodine Fumarate ErFesoterodine Fumarate40$4,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,360$1,842,055289 claims
Sumitomo Pharma America, Inc.Gemtesa$861$322,302333 claims
PfizerToviaz$1,086$3,84013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 196 urology providers in South Carolina.

Other urology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →